|Highlights of CFDA’s Plan To Implement Review and Approval System Reform and Encourage Drug and Medical Device Innovation in China|
|In October 2017, China’s Central Government’s State Council promulgated The Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation. In accordance, CFDA Director Mr. Bi Jingquan held a Videophone Conference to explain and make necessary arrangements for his agency to implement the mandatory opinions. In his speech, the CFDA Director covered three areas with the following important points:
China Med Device thinks that the CFDA is making the right start by recognizing the importance of and planning for concrete measures to implement The Opinions. The effect of reform implementations and measures to protect overseas device manufacturers’ innovations remains to be seen. But with success even on a limited scale, this will be a quantum leap on China’s part to open its doors wider to overseas medical device companies, which in turn will help meet the growing healthcare demands of the Chinese people.
About China Med Device, LLC (CMD): CMD provides turn-key solution for Western medtech companies with regulatory and commercialization services. CMD helps its clients accelerate China entry and growth by offering: market Intelligence and research; CFDA regulatory services (premarket submission, clinical evaluation, clinical trial design & management, post market compliance and legal representation), and other commercial services. If you have an inquiry or feedback regarding our services please email us at info@ChinaMedDevice.com.